Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation

2018-2022
Written By RRCU Staff

Download the PDF

Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A, Damasceno A, Avezum A, Dans AML, Gitura B, Hu D, Kamanzi ER, Maklady F, Fana G, Gonzalez-Hermosillo JA, Musuku J, Kazmi K, Zuhlke L, Gondwe L, Ma C, Paniagua M, Ogah OS, Molefe-Baikai OJ, Lwabi P, Chillo P, Sharma SK, Cabral TTJ, Tarhuni WM, Benz A, van Eikels M, Krol A, Pattath D, Balasubramanian K, Rangarajan S, Ramasundarahettige C, Mayosi B, Yusuf S and Investigators I. Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.

N Engl J Med. 2022.

RRCU Staff
Previous

Positive impact of training rural health workers in identification and prevention of acute rheumatic fever in eastern Uganda
Next

Clinical Outcomes, Echocardiographic Findings, and Care Quality Metrics for People Living With Human Immunodeficiency Virus (HIV) and Rheumatic Heart Disease in Uganda